Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center www.cccancer.com Wichita,

Slides:



Advertisements
Similar presentations
Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized.
Advertisements

Serena T. Wong, MD Assistant Professor of Medicine
Advances and Emerging Therapy for Lung Cancer
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Oncotype DX® Breast Cancer Assay Clinical Data Review
Triple negative breast cancer
Oncologic Drugs Advisory Committee
Triple-Negative Breast Cancer
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Treatment in Advanced Non-Small Cell Lung Cancer.
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.
Targeted Therapy: A Giant Step Forward
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
OVARIAN CANCER Talking point: Genetics of ovarian cancer.
Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Genetic and Molecular Epidemiology
2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!
Panagiotis Konstantinopoulos MD, PhD Assistant Professor of Medicine
Future therapeutic approaches for metastatic triple negative breast cancer 18th Annual Perspective in Breast Cancer New York, August 18th, 2012 Ruth M.
These slides were released by the speaker for internal use by Novartis.
Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.
First Safety Data from a Randomized Phase III (CIBOMA/ /GEICAM ) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard.
Phase 1b Study of Iniparib (BSI-201) Combined with Irinotecan for Treatment of Metastatic Breast Cancer 1 Cell Cycle Effects of Iniparib plus Gemcitabine.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Epidemiology. Definition Biology “Basal-Like” The “Triple Negative” Breast Cancer Estrogen Receptor (ER) negative Progesterone receptor (PR) negative.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P
Adjuvant systemic therapy in breast cancer Targeted therapies Update R. Paridaens Belgian Breast Meeting
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Indivisualized approach for brain surveillance in high-risk breast cancer patients Soohyeon Lee Yonsei Cancer Center Severance Hospital Division of Medical.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Basal Type Breast Adenocarcinoma Eva Desmond DT204/2 C
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Breast cancer Not a single disease. Type and stage. Grade/Lympho-vascular invasion Molecular biology. ER\PR Her-2-neu Other. Gene expression profiling.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
Department of Surgical, Oncological and Oral Sciences U.O.C Medical Oncology Director: Prof A. Russo Ovarian cancer Case Report 1 Dr. Lorena Incorvaia,
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Adjuvant Therapy of Triple Negative Breast Cancer
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
Az Ospedaliero Universitaria di Ferrara
An Introduction to DNA Damage Repair in Cancer: Beyond PARP
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Jones SE et al. SABCS 2009;Abstract 5082.
Managing gBRCA-Positive Metastatic Breast Cancer
Optimizing Neoadjuvant Treatment for Primary Breast Cancer
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Clinical Focus.
Presentation transcript:

Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS - USA

Molecular Subtypes of Breast Cancer 1. Luminal A: ER+ and or PR+ Her2 -ve 2. Luminal B: ER+ and or PR + Her2+ 3. Her2: Her2+ ER-ve PR-ve 4. Basal-like: ER-ve PR-ve Her2-ve, cytokeratin 5/6+, and or Her1+ 5. Normal-like: negative for all markers

Basal-like tumors Mostly ER/HER2–negative Marked increases in mitotic count, geographic necrosis Pushing borders of invasion Stromal lymphocytic response

BRCA1, BRAC2 Mutation Carrier BRCA1: Chromosome 17 57% risk of breast, 40% ov ca Bil breast ca ER-PR –ve Higher G Basal-like BRCA 2: Chromosome 13 49% risk of breast, 18% ov ca Pancreatic, prost, bile/GB, stomach ER/PR +ve BRCA 1-2: 2/3 - 3/5 of familial breast ca 50-87% risk of invasive breast ca % risk of invasive epith ovarian ca

Epidemiology In 2008, it is estimated that over 1 million women worldwide will be diagnosed with breast cancer, of which 172,695 will be classified as “triple-negative.

TNBC ER/PR/Her2-neu negative It is characterized by: unique molecular profile majority carry the “basal-like” molecular profile on gene expression arrays majority of BRCA1-associated breast cancers are TN and basal-like majority of BRCA1-associated breast cancers are TN and basal-like the extent to which the BRCA1 pathway contributes to the behavior of sporadic basal-like breast cancers is an area of active research aggressive behavior younger age higher mean tumor size higher-G higher rate of node positivity distinct patterns of metastasis Early relapse Predilection for visceral metastasis, including brain lack of targeted therapies

TNBC Increasing evidence suggests that the risk factor profile differs between this subtype and the more common luminal subtypes.

TNBC Although sensitive to chemotherapy, early relapse is common Targeted agents, (EGFR, VEGF, PARP) inhibitors, are currently in clinical trials and hold promise in the treatment of this aggressive disease

Relationship between TNBC, BRCA and Basal-like phenotype Triple-negative is a term based on clinical assays for ER, PR, and HER2 Basal-like is a molecular phenotype initially defined using cDNA microarrays characterized by low expression of ER, PR, and HER2 Not all TNBC are basal-like Majority of BRCA1-associated breast cancers are triple-negative and express a high proportion of basal-like cytokeratins

Current Treatment for Metastatic TNBC No FDA-approved treatment option specifically for metastatic TNBC Limited treatment options for metastatic TNBC –Most patients already treated with adjuvant anthracycline, taxane, and cyclophosphamide –PFS ≤ 4 mos with chemotherapy for metastatic disease Rationale for gemcitabine/ carboplatin in MBC –Synergistic antitumor activity between gemcitabine and carboplatin –Active combination in MBC, with response rates from 21% to 53% Rationale for PARP inhibitor– based therapy in TNBC –PARP1 is upregulated in majority of triple-negative human breast cancers 1. Kassam F, et al. Clin Breast Cancer. 2009;9: Li HC, et al. Oncology (Williston Park). 2004;18(14 suppl 12): Loesch D, et al. Clin Breast Cancer. 2008;8:

Anthracycline/Taxane–Based Chemotherapy Two neoadjuvant studies: proportionally higher sensitivity to anthracycline- or anthracycline/taxane–based chemo for basal-like/ER- negative breast cancers compared to luminal/ER-positive subtypes Despite initial chemosensitivity, DFS (P =.04) and OS (P =.02) remained poorest among those with basal-like and HER2-positive tumors compared to luminal tumors Pts with a pCR had excellent outcomes regardless of subtype Pts with a pCR had excellent outcomes regardless of subtype the poorer outcome among triple-negative patients was attributed to a higher rate of recurrence among patients with residual disease

Platinum Tumors with BRCA1 dysfunction harboring deficient double-stranded DNA break repair mechanisms are sensitive to agents that cause DNA damage, such as platinum agents* *Garber J, Richardson A, Harris L, et al: Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC) (abstract 3074). Breast Cancer Res Treat 100(suppl 1), *Sirohi B, Arnedos M, Popat S, et al: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol June 20, 2008 (epub ahead of print). *Yi S, Uhm J, Cho E, et al: Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum- containing chemotherapy (abstract 1008). J Clin Oncol 26(15S):43s, 2008.

Targeted Strategies EGFR expression is seen in approximately 60% of TNBC phase II trial (cetuximab + carbo): 18% RR, 27% overall clinical benefit rate 18% RR, 27% overall clinical benefit rate CPT11/carbo +/- cetuximab 49% vs 30% RR

THANKS